228 related articles for article (PubMed ID: 11519042)
1. Antagonistic effects of c-myc and Epstein-Barr virus latent genes on the phenotype of human B cells.
Pajic A; Staege MS; Dudziak D; Schuhmacher M; Spitkovsky D; Eissner G; Brielmeier M; Polack A; Bornkamm GW
Int J Cancer; 2001 Sep; 93(6):810-6. PubMed ID: 11519042
[TBL] [Abstract][Full Text] [Related]
2. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1.
Polack A; Hörtnagel K; Pajic A; Christoph B; Baier B; Falk M; Mautner J; Geltinger C; Bornkamm GW; Kempkes B
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10411-6. PubMed ID: 8816814
[TBL] [Abstract][Full Text] [Related]
3. Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines.
Floettmann JE; Ward K; Rickinson AB; Rowe M
Virology; 1996 Sep; 223(1):29-40. PubMed ID: 8806537
[TBL] [Abstract][Full Text] [Related]
4. Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts.
Cutrona G; Ulivi M; Fais F; Roncella S; Ferrarini M
J Exp Med; 1995 Feb; 181(2):699-711. PubMed ID: 7836923
[TBL] [Abstract][Full Text] [Related]
5. c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.
Faumont N; Durand-Panteix S; Schlee M; Grömminger S; Schuhmacher M; Hölzel M; Laux G; Mailhammer R; Rosenwald A; Staudt LM; Bornkamm GW; Feuillard J
J Virol; 2009 May; 83(10):5014-27. PubMed ID: 19264782
[TBL] [Abstract][Full Text] [Related]
6. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.
Schlee M; Krug T; Gires O; Zeidler R; Hammerschmidt W; Mailhammer R; Laux G; Sauer G; Lovric J; Bornkamm GW
J Virol; 2004 Apr; 78(8):3941-52. PubMed ID: 15047810
[TBL] [Abstract][Full Text] [Related]
7. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
[TBL] [Abstract][Full Text] [Related]
8. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
Price AM; Messinger JE; Luftig MA
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
[TBL] [Abstract][Full Text] [Related]
9. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
10. Activated Notch1 modulates gene expression in B cells similarly to Epstein-Barr viral nuclear antigen 2.
Strobl LJ; Höfelmayr H; Marschall G; Brielmeier M; Bornkamm GW; Zimber-Strobl U
J Virol; 2000 Feb; 74(4):1727-35. PubMed ID: 10644343
[TBL] [Abstract][Full Text] [Related]
11. Notch1IC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus.
Gordadze AV; Peng R; Tan J; Liu G; Sutton R; Kempkes B; Bornkamm GW; Ling PD
J Virol; 2001 Jul; 75(13):5899-912. PubMed ID: 11390591
[TBL] [Abstract][Full Text] [Related]
12. Dual EBNA1 promoter usage by Epstein-Barr virus in human B-cell lines expressing unique intermediate cellular phenotypes.
Taylor KA; Wetzel S; Lyles DS; Pollok BA
J Virol; 1994 Oct; 68(10):6421-31. PubMed ID: 8083980
[TBL] [Abstract][Full Text] [Related]
13. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis.
Peng M; Lundgren E
Oncogene; 1992 Sep; 7(9):1775-82. PubMed ID: 1354347
[TBL] [Abstract][Full Text] [Related]
14. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
Cordier M; Calender A; Billaud M; Zimber U; Rousselet G; Pavlish O; Banchereau J; Tursz T; Bornkamm G; Lenoir GM
J Virol; 1990 Mar; 64(3):1002-13. PubMed ID: 2154588
[TBL] [Abstract][Full Text] [Related]
15. Elevated expression of c-myc in lymphoblastoid cells does not support an Epstein-Barr virus latency III-to-I switch.
Pajic A; Polack A; Staege MS; Spitkovsky D; Baier B; Bornkamm GW; Laux G
J Gen Virol; 2001 Dec; 82(Pt 12):3051-3055. PubMed ID: 11714983
[TBL] [Abstract][Full Text] [Related]
16. Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV).
Calender A; Cordier M; Billaud M; Lenoir GM
Int J Cancer; 1990 Oct; 46(4):658-63. PubMed ID: 1698730
[TBL] [Abstract][Full Text] [Related]
17. Restricted expression of Epstein-Barr virus (EBV)-encoded, growth transformation-associated antigens in an EBV- and human herpesvirus type 8-carrying body cavity lymphoma line.
Szekely L; Chen F; Teramoto N; Ehlin-Henriksson B; Pokrovskaja K; Szeles A; Manneborg-Sandlund A; Löwbeer M; Lennette ET; Klein G
J Gen Virol; 1998 Jun; 79 ( Pt 6)():1445-52. PubMed ID: 9634087
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
Kelly G; Bell A; Rickinson A
Nat Med; 2002 Oct; 8(10):1098-104. PubMed ID: 12219084
[TBL] [Abstract][Full Text] [Related]
19. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
